APO Research
Talk to an analyst

APO RESEARCH · REPORT

Montelukast Intermediate

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Montelukast Intermediate Market Outlook and Growth Opportunities 2026

20 December 2025193 pages

Choose your research edition.

Industry ResearchMontelukast Intermediate Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Montelukast Intermediate Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Montelukast Intermediate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Montelukast Intermediate Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Montelukast Intermediate Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Montelukast Intermediate market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Montelukast Intermediate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Montelukast Intermediate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Montelukast Intermediate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Montelukast Intermediate market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Montelukast Intermediate market include VIVAN Life Sciences, P.G. Shah & Co., Ortin Laboratories and Manus Aktteva Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Montelukast Intermediate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Montelukast Intermediate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Montelukast Intermediate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Montelukast Intermediate market size, projected growth trends, production technologies, key applications, and end-use industries.

Montelukast Intermediate Segment by Company

VIVAN Life Sciences

P.G. Shah & Co.

Ortin Laboratories

Manus Aktteva Biopharma

Montelukast Intermediate Segment by Type

GMP

Non-GMP

Montelukast Intermediate Segment by Application

Bronchospasm

Urticaria

Asthma

Allergic Rhinitis

Montelukast Intermediate Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Montelukast Intermediate status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Montelukast Intermediate market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Montelukast Intermediate significant trends, drivers, influence factors in global and regions.

6. To analyze Montelukast Intermediate competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Montelukast Intermediate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Montelukast Intermediate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Montelukast Intermediate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Montelukast Intermediate market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Montelukast Intermediate industry.

Chapter 3: Detailed analysis of Montelukast Intermediate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Montelukast Intermediate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Montelukast Intermediate in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Montelukast Intermediate Industry Trends Table 2. Montelukast Intermediate Industry Drivers Table 3. Montelukast Intermediate Industry Opportunities and Challenges Table 4. Montelukast Intermediate Industry Restraints Table 5. Global Montelukast Intermediate Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Montelukast Intermediate Revenue Share by Company (2021-2026) Table 7. Global Montelukast Intermediate Sales Volume by Company (tons) & (2021-2026) Table 8. Global Montelukast Intermediate Sales Volume Share by Company (2021-2026) Table 9. Global Montelukast Intermediate Average Price (US$/ton) of Company (2021-2026) Table 10. Global Montelukast Intermediate Company Ranking, (2024-2026) & (USD Million) Table 11. Global Montelukast Intermediate Key Company Manufacturing Base & Headquarters Table 12. Global Montelukast Intermediate Company, Product Type & Application Table 13. Global Montelukast Intermediate Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Montelukast Intermediate by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of GMP Table 18. Significant Companies of Non-GMP Table 19. Global Montelukast Intermediate Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 20. Global Montelukast Intermediate Sales Volume by Type (2021-2026) & (tons) Table 21. Global Montelukast Intermediate Sales Volume by Type (2027-2032) & (tons) Table 22. Global Montelukast Intermediate Sales Volume Share by Type (2021-2026) Table 23. Global Montelukast Intermediate Sales Volume Share by Type (2027-2032) Table 24. Global Montelukast Intermediate Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Montelukast Intermediate Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Montelukast Intermediate Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Montelukast Intermediate Sales Value Share by Type (2021-2026) Table 28. Global Montelukast Intermediate Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Bronchospasm Table 30. Significant Companies of Urticaria Table 31. Significant Companies of Asthma Table 32. Significant Companies of Allergic Rhinitis Table 33. Global Montelukast Intermediate Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 34. Global Montelukast Intermediate Sales Volume by Application (2021-2026) & (tons) Table 35. Global Montelukast Intermediate Sales Volume by Application (2027-2032) & (tons) Table 36. Global Montelukast Intermediate Sales Volume Share by Application (2021-2026) Table 37. Global Montelukast Intermediate Sales Volume Share by Application (2027-2032) Table 38. Global Montelukast Intermediate Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Montelukast Intermediate Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Montelukast Intermediate Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Montelukast Intermediate Sales Value Share by Application (2021-2026) Table 42. Global Montelukast Intermediate Sales Value Share by Application (2027-2032) Table 43. Global Montelukast Intermediate Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 44. Global Montelukast Intermediate Sales by Region (2021-2026) & (tons) Table 45. Global Montelukast Intermediate Sales Market Share by Region (2021-2026) Table 46. Global Montelukast Intermediate Sales by Region (2027-2032) & (tons) Table 47. Global Montelukast Intermediate Sales Market Share by Region (2027-2032) Table 48. Global Montelukast Intermediate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Montelukast Intermediate Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Montelukast Intermediate Sales Value Share by Region (2021-2026) Table 51. Global Montelukast Intermediate Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Montelukast Intermediate Sales Value Share by Region (2027-2032) Table 53. Global Montelukast Intermediate Market Average Price (US$/ton) by Region (2021-2026) Table 54. Global Montelukast Intermediate Market Average Price (US$/ton) by Region (2027-2032) Table 55. Global Montelukast Intermediate Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 56. Global Montelukast Intermediate Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Montelukast Intermediate Sales by Country (2021-2026) & (tons) Table 58. Global Montelukast Intermediate Sales Market Share by Country (2021-2026) Table 59. Global Montelukast Intermediate Sales by Country (2027-2032) & (tons) Table 60. Global Montelukast Intermediate Sales Market Share by Country (2027-2032) Table 61. Global Montelukast Intermediate Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Montelukast Intermediate Sales Value Market Share by Country (2021-2026) Table 63. Global Montelukast Intermediate Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Montelukast Intermediate Sales Value Market Share by Country (2027-2032) Table 65. VIVAN Life Sciences Company Information Table 66. VIVAN Life Sciences Business Overview Table 67. VIVAN Life Sciences Montelukast Intermediate Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 68. VIVAN Life Sciences Montelukast Intermediate Product Portfolio Table 69. VIVAN Life Sciences Recent Development Table 70. P.G. Shah & Co. Company Information Table 71. P.G. Shah & Co. Business Overview Table 72. P.G. Shah & Co. Montelukast Intermediate Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 73. P.G. Shah & Co. Montelukast Intermediate Product Portfolio Table 74. P.G. Shah & Co. Recent Development Table 75. Ortin Laboratories Company Information Table 76. Ortin Laboratories Business Overview Table 77. Ortin Laboratories Montelukast Intermediate Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 78. Ortin Laboratories Montelukast Intermediate Product Portfolio Table 79. Ortin Laboratories Recent Development Table 80. Manus Aktteva Biopharma Company Information Table 81. Manus Aktteva Biopharma Business Overview Table 82. Manus Aktteva Biopharma Montelukast Intermediate Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 83. Manus Aktteva Biopharma Montelukast Intermediate Product Portfolio Table 84. Manus Aktteva Biopharma Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Montelukast Intermediate Distributors List Table 88. Montelukast Intermediate Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Montelukast Intermediate Product Image Figure 2. Global Montelukast Intermediate Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Montelukast Intermediate Sales Value (2021-2032) & (US$ Million) Figure 4. Global Montelukast Intermediate Sales (2021-2032) & (tons) Figure 5. Global Montelukast Intermediate Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Montelukast Intermediate Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. GMP Image Figure 10. Non-GMP Image Figure 11. Global Montelukast Intermediate Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 12. Global Montelukast Intermediate Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Montelukast Intermediate Sales Volume Share by Type (2021-2032) Figure 14. Global Montelukast Intermediate Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Montelukast Intermediate Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Montelukast Intermediate Sales Value Share by Type (2021-2032) Figure 17. Bronchospasm Image Figure 18. Urticaria Image Figure 19. Asthma Image Figure 20. Allergic Rhinitis Image Figure 21. Global Montelukast Intermediate Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 22. Global Montelukast Intermediate Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Montelukast Intermediate Sales Volume Share by Application (2021-2032) Figure 24. Global Montelukast Intermediate Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Montelukast Intermediate Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Montelukast Intermediate Sales Value Share by Application (2021-2032) Figure 27. Global Montelukast Intermediate Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 28. Global Montelukast Intermediate Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Montelukast Intermediate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Montelukast Intermediate Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Montelukast Intermediate Sales Value (2021-2032) & (US$ Million) Figure 32. North America Montelukast Intermediate Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Montelukast Intermediate Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Montelukast Intermediate Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Montelukast Intermediate Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Montelukast Intermediate Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Montelukast Intermediate Sales Value (2021-2032) & (US$ Million) Figure 38. South America Montelukast Intermediate Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Montelukast Intermediate Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Montelukast Intermediate Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Montelukast Intermediate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Montelukast Intermediate Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Montelukast Intermediate Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • GMP
  • Non-GMP
Applications
  • Bronchospasm
  • Urticaria
  • Asthma
  • Allergic Rhinitis
Companies covered
  • VIVAN Life Sciences
  • P.G. Shah & Co.
  • Ortin Laboratories
  • Manus Aktteva Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Montelukast Intermediate Sales Value (2021-2032)
  4. 1.2.2 Global Montelukast Intermediate Sales Volume (2021-2032)
  5. 1.2.3 Global Montelukast Intermediate Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Montelukast Intermediate Market Dynamics
  1. 2.1 Montelukast Intermediate Industry Trends
  2. 2.2 Montelukast Intermediate Industry Drivers
  3. 2.3 Montelukast Intermediate Industry Opportunities and Challenges
  4. 2.4 Montelukast Intermediate Industry Restraints
3 Montelukast Intermediate Market by Company
  1. 3.1 Global Montelukast Intermediate Company Revenue Ranking in 2025
  2. 3.2 Global Montelukast Intermediate Revenue by Company (2021-2026)
  3. 3.3 Global Montelukast Intermediate Sales Volume by Company (2021-2026)
  4. 3.4 Global Montelukast Intermediate Average Price by Company (2021-2026)
  5. 3.5 Global Montelukast Intermediate Company Ranking (2024-2026)
  6. 3.6 Global Montelukast Intermediate Company Manufacturing Base and Headquarters
  7. 3.7 Global Montelukast Intermediate Company Product Type and Application
  8. 3.8 Global Montelukast Intermediate Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Montelukast Intermediate Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Montelukast Intermediate Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Montelukast Intermediate Market by Type
  1. 4.1 Montelukast Intermediate Type Introduction
  2. 4.1.1 GMP
  3. 4.1.2 Non-GMP
  4. 4.2 Global Montelukast Intermediate Sales Volume by Type
  5. 4.2.1 Global Montelukast Intermediate Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Montelukast Intermediate Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Montelukast Intermediate Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Montelukast Intermediate Sales Value by Type
  9. 4.3.1 Global Montelukast Intermediate Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Montelukast Intermediate Sales Value by Type (2021-2032)
  11. 4.3.3 Global Montelukast Intermediate Sales Value Share by Type (2021-2032)
5 Montelukast Intermediate Market by Application
  1. 5.1 Montelukast Intermediate Application Introduction
  2. 5.1.1 Bronchospasm
  3. 5.1.2 Urticaria
  4. 5.1.3 Asthma
  5. 5.1.4 Allergic Rhinitis
  6. 5.2 Global Montelukast Intermediate Sales Volume by Application
  7. 5.2.1 Global Montelukast Intermediate Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Montelukast Intermediate Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Montelukast Intermediate Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Montelukast Intermediate Sales Value by Application
  11. 5.3.1 Global Montelukast Intermediate Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Montelukast Intermediate Sales Value by Application (2021-2032)
  13. 5.3.3 Global Montelukast Intermediate Sales Value Share by Application (2021-2032)
6 Montelukast Intermediate Regional Sales and Value Analysis
  1. 6.1 Global Montelukast Intermediate Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Montelukast Intermediate Sales by Region (2021-2032)
  3. 6.2.1 Global Montelukast Intermediate Sales by Region: 2021-2026
  4. 6.2.2 Global Montelukast Intermediate Sales by Region (2027-2032)
  5. 6.3 Global Montelukast Intermediate Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Montelukast Intermediate Sales Value by Region (2021-2032)
  7. 6.4.1 Global Montelukast Intermediate Sales Value by Region: 2021-2026
  8. 6.4.2 Global Montelukast Intermediate Sales Value by Region (2027-2032)
  9. 6.5 Global Montelukast Intermediate Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Montelukast Intermediate Sales Value (2021-2032)
  12. 6.6.2 North America Montelukast Intermediate Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Montelukast Intermediate Sales Value (2021-2032)
  15. 6.7.2 Europe Montelukast Intermediate Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Montelukast Intermediate Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Montelukast Intermediate Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Montelukast Intermediate Sales Value (2021-2032)
  21. 6.9.2 South America Montelukast Intermediate Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Montelukast Intermediate Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Montelukast Intermediate Sales Value Share by Country, 2025 VS 2032
7 Montelukast Intermediate Country-level Sales and Value Analysis
  1. 7.1 Global Montelukast Intermediate Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Montelukast Intermediate Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Montelukast Intermediate Sales by Country (2021-2032)
  4. 7.3.1 Global Montelukast Intermediate Sales by Country (2021-2026)
  5. 7.3.2 Global Montelukast Intermediate Sales by Country (2027-2032)
  6. 7.4 Global Montelukast Intermediate Sales Value by Country (2021-2032)
  7. 7.4.1 Global Montelukast Intermediate Sales Value by Country (2021-2026)
  8. 7.4.2 Global Montelukast Intermediate Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Montelukast Intermediate Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Montelukast Intermediate Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Montelukast Intermediate Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 VIVAN Life Sciences
  2. 8.1.1 VIVAN Life Sciences Company Information
  3. 8.1.2 VIVAN Life Sciences Business Overview
  4. 8.1.3 VIVAN Life Sciences Montelukast Intermediate Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 VIVAN Life Sciences Montelukast Intermediate Product Portfolio
  6. 8.1.5 VIVAN Life Sciences Recent Developments
  7. 8.2 P.G. Shah & Co.
  8. 8.2.1 P.G. Shah & Co. Company Information
  9. 8.2.2 P.G. Shah & Co. Business Overview
  10. 8.2.3 P.G. Shah & Co. Montelukast Intermediate Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 P.G. Shah & Co. Montelukast Intermediate Product Portfolio
  12. 8.2.5 P.G. Shah & Co. Recent Developments
  13. 8.3 Ortin Laboratories
  14. 8.3.1 Ortin Laboratories Company Information
  15. 8.3.2 Ortin Laboratories Business Overview
  16. 8.3.3 Ortin Laboratories Montelukast Intermediate Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ortin Laboratories Montelukast Intermediate Product Portfolio
  18. 8.3.5 Ortin Laboratories Recent Developments
  19. 8.4 Manus Aktteva Biopharma
  20. 8.4.1 Manus Aktteva Biopharma Company Information
  21. 8.4.2 Manus Aktteva Biopharma Business Overview
  22. 8.4.3 Manus Aktteva Biopharma Montelukast Intermediate Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Manus Aktteva Biopharma Montelukast Intermediate Product Portfolio
  24. 8.4.5 Manus Aktteva Biopharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Montelukast Intermediate Value Chain Analysis
  2. 9.1.1 Montelukast Intermediate Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Montelukast Intermediate Sales Mode & Process
  6. 9.2 Montelukast Intermediate Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Montelukast Intermediate Distributors
  9. 9.2.3 Montelukast Intermediate Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst